Latest Innovation News

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

Beonic Limited has secured a $7.3 million contract phase for its Moroccan Airports project, completed a $4.27 million capital raise, and fully repaid a $4.65 million USD loan, underpinning its continued EBITDA profitability and positive cash flow.

Nanollose has advanced its largest pilot production of Nullarbor™ fibre, integrating a refined microbial cellulose process that promises easier adoption by textile manufacturers. The company also bolstered its intellectual property portfolio and secured additional funding post-quarter.

Dotz Nano has achieved a key production milestone for its proprietary CO2 sorbent materials and raised over AU$3 million to accelerate commercialization of its DotzEarth technology.

Elders Limited delivered a resilient FY25 performance with 12% EBIT growth and a strategic focus on diversification and leverage reduction. The company’s Fourth Eight Point Plan drives operational optimisation and expansion across agribusiness divisions.

Anatara Lifesciences reports encouraging interim pre-clinical results for its Anti-Obesity Project, with a candidate compound showing significant effects on weight regain and visceral fat in mice. The company also completed a $1.2 million capital raise, bolstering its financial position as it advances research.

Iondrive Limited has marked a pivotal shift from development to commercialisation of its IONSolv™ technology, securing $4 million to target the US e-waste market and commissioning its pilot plant to refine critical minerals.

AnteoTech has marked significant progress in battery and life sciences sectors, highlighted by a major capital raise and strategic US partnership. The company is poised to convert promising trials into sales amid expanding market opportunities.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Mach7 Technologies reports a positive operating cash flow in Q2 FY26, securing its first customer for the new Flamingo Architecture product and advancing key strategic initiatives.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

Lotus Resources reports steady progress at its Kayelekera uranium mine despite supply challenges, while its Letlhakane project shows promising metallurgical advances. The company targets full production and first shipments in the second quarter of 2026.